Literature DB >> 54389

Antigenic determinants of adenovirus capsids. II. Homogeneity of hexons, and accessibility of their determinants, in the virion.

N Willcox, V Mautner.   

Abstract

We have tested the two principal theories which explain the previous finding that small amounts of type-specific antibody to the adenovirus hexon can neutralize infectivity, whereas even large amounts of cross-reactive antibody do not. a) It has been suggested that the type-specific determinants are especially prominent in the virion. We have therefore measured the capacity of whole virus to bind appropriate antibodies, using a sensitive radioimmunoprecipitation (RIP) system. In fact, virions bound type-specific and cross-reactive antibodies impartially. Moreover, they bound both much less effectively than did free hexon or disrupted virus, suggesting that many of each kind of determinant are inaccessible in virions. b) It has been suggested that the type-specific determinants are confined to those hexons located next to the pentons, and that they are the targets for neutralizing antibody. We have therefore studied the antigenicity of peripentonal and nonamer hexons isolated from virions, and found that each possessed both kinds of determinants. Furthermore, these were present in the same proportion as in hexons purified from the soluble antigens in infected cells ("free hexons"). We concluded that the mechanism of neutralization by antibody is complicated, and that the type-specific determinants exposed on the virion must play a crucial role.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 54389

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Sequence of the avian adenovirus FAV 1 (CELO) DNA encoding the hexon-associated protein pVI and hexon.

Authors:  T A Akopian; K K Doronin; V A Karpov; B S Naroditsky
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

2.  The effect of adenovirus-specific antibodies on adenoviral vector-induced, transgene product-specific T cell responses.

Authors:  Juliana C Small; Larissa H Haut; Ang Bian; Hildegund C J Ertl
Journal:  J Leukoc Biol       Date:  2014-07-31       Impact factor: 4.962

3.  Preparation and characterization of monoclonal antibodies to enteric adenovirus types 40 and 41.

Authors:  J E Herrmann; D M Perron-Henry; D Stobbs-Walro; N R Blacklow
Journal:  Arch Virol       Date:  1987       Impact factor: 2.574

4.  Evidence that the penton base of adenovirus is involved in potentiation of toxicity of Pseudomonas exotoxin conjugated to epidermal growth factor.

Authors:  P Seth; D Fitzgerald; H Ginsberg; M Willingham; I Pastan
Journal:  Mol Cell Biol       Date:  1984-08       Impact factor: 4.272

5.  Canine adenovirus type 2 attachment and internalization: coxsackievirus-adenovirus receptor, alternative receptors, and an RGD-independent pathway.

Authors:  C Soudais; S Boutin; S S Hong; M Chillon; O Danos; J M Bergelson; P Boulanger; E J Kremer
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Neutralization of reovirus: the gene responsible for the neutralization antigen.

Authors:  H L Weiner; B N Fields
Journal:  J Exp Med       Date:  1977-11-01       Impact factor: 14.307

7.  Interaction between HeLa cells and adenovirus type 2 virions neutralized by different antisera.

Authors:  C E Wohlfart; U K Svensson; E Everitt
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

8.  Use of oligonucleotide microarrays for rapid detection and serotyping of acute respiratory disease-associated adenoviruses.

Authors:  Baochuan Lin; Gary J Vora; Dzung Thach; Elizabeth Walter; David Metzgar; Clark Tibbetts; David A Stenger
Journal:  J Clin Microbiol       Date:  2004-07       Impact factor: 5.948

9.  Construction and characterization of hexon-chimeric adenoviruses: specification of adenovirus serotype.

Authors:  J G Gall; R G Crystal; E Falck-Pedersen
Journal:  J Virol       Date:  1998-12       Impact factor: 5.103

10.  Small-size recombinant adenoviral hexon protein fragments for the production of virus-type specific antibodies.

Authors:  Martin Pacesa; Rodinde Hendrickx; Manuela Bieri; Justin W Flatt; Urs F Greber; Silvio Hemmi
Journal:  Virol J       Date:  2017-08-18       Impact factor: 4.099

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.